Previous 10 | Next 10 |
Gainers: SunLink Health Systems (SSY) +219%.Can-Fite BioPharma (CANF) +53%.Savara (SVRA) +37%.Fintech Acquisition (FTCVU) +31%.New Fortress Energy (NFE) +27%.Lizhi (LIZI) +26%.Enzo Biochem (ENZ) +25%.iSun (ISUN) +23%.Anchiano Therapeutics (ANCN) +21%.OptimizeRx (OPRX) +21%...
Gainers: SunLink Health Systems (SSY) +161%, Can-Fite BioPharma (CANF) +61%, Streamline Health Solutions (STRM) +56%, Anchiano Therapeutics (ANCN) +40%, Enzo Biochem (ENZ) +39%.Losers: Solid Biosciences (SLDB) -31%, Zynerba Pharmaceu...
These 5 Reopening Penny Stocks Popped in 2021 Penny stocks have been one way for traders to take advantage of the stock market’s volatility. Typically, we define these as stocks under $5 , but since the pandemic, the makeup of these cheap stocks has changed. What I mean by th...
Can-Fite BioPharma Ltd. (CANF) +87% on out-licensing psoriasis, liver disease drug rights.SunLink Health Systems, Inc. (SSY) +55% on announcing $2 Million expansion, capital and operating improvements at Trace Regional Hospital.Annovis Bio, Inc. (ANVS) +37% as ANVS401 improves ...
Enzo Biochem, Inc. (ENZ) Q2 2021 Earnings Conference Call March 15, 2021, 04:30 PM ET Company Participants Jeremy Feffer - Investor Relations Barry Weiner - Co-Founder and President David Bench - CFO Conference Call Participants Paul Knight - KeyBanc Keith Maher - Armistice Capital Presentati...
Enzo Biochem (ENZ) has climbed 58.5% in the post-market after announcing the departure of its Elazar Rabbani.The founder of Enzo will remain as a director of the company and take up a scientific role after the board hires a suitable candidate for the position.The company has retaine...
Enzo Biochem (ENZ): FQ2 Non-GAAP EPS of $0.09; GAAP EPS of $0.05.Revenue of $31.47M (+62.4% Y/Y)Shares +31.7%.Press Release For further details see: Enzo Biochem reports FQ2 results
Total second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemic Second quarter clinical laboratory revenue of $24.0 million increased 92% on significant volume and pricing growth due to improved pr...
NEW YORK, NY, March 04, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Company will present at H.C. Wainwright Global Life Sciences Conference, which is bei...
Results indicate that GENFLEX meets new FDA guidance calling for COVID-19 test developers to assess the impact of viral mutations on testing results Company also publishes new corporate white paper outlining deficiencies in U.S. diagnostics sector’s response to COVID-19 and...
News, Short Squeeze, Breakout and More Instantly...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's...
FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fis...